10:56am ET
Health and Healthcare
How Sarepta and Selecta Bio Are Taking the Fight to DMD
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Chris Lange
Companies
/Healthcare
Sarepta Therapeutics Inc
$20.86
▼ $0.73 (−3.38%) today
Markets closed · 3:24am ET
SRPT Coverage
Page 3 Chris Lange 7:05am ET
Health and Healthcare
Biotech Stocks Seeing the Biggest Boost From Coronavirus Outbreak
Here are the biotech companies with exposure to experimental vaccines whose shares saw the biggest boost from this past week's coronavirus news.
1:00pm ET
Health and Healthcare
China’s Coronavirus Could Prompt Buying Frenzy in These Biotech Stocks
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
12:30pm ET
Health and Healthcare
Why One Analyst Sees Sarepta’s Roche Deal Taking Off
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside…
Chris Lange 9:00am ET
Investing
Top Analyst Upgrades and Downgrades: Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron, Sarpeta and More
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
10:20am ET
Health and Healthcare
Why This Duchenne Muscular Dystropy Deal Could Be Huge
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Chris Lange 10:10am ET
Health and Healthcare
Sarepta Catches a Big Break With Duchenne Muscular Dystrophy Drug
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.
Chris Lange 9:00am ET
Investing
Top Analyst Upgrades and Downgrades: Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap, Wayfair and More
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
9:05am ET
Investing
Top Analyst Upgrades and Downgrades: Arista, Booking, Dunkin, DuPont, GameStop, Generac, PBF Energy, Pinterest, Square, YETI and More
Friday's top analyst upgrades, downgrades and initiations included Arista Networks, Booking, Dunkin' Brands, DuPont, GameStop, Generac, PBF Energy, Pinterest, Square and YETI.
10:55am ET
Health and Healthcare
More Good News for LGMD Patients
Sarepta shares jumped on Friday after the firm announced an update from its Duchenne muscular dystrophy trial.
Chris Lange 7:25am ET
Health and Healthcare
Top Baird Health Care and Biotech Picks Have Massive Upside Potential
One sector that has avoided much of the current trade and recession fear turmoil is health care, and especially the biotech companies. The four top stocks have gigantic implied upside.
1:30pm ET
Health and Healthcare
4 Biotechs Making Major Moves on Tuesday
Tuesday was a breakout day for a few biotech companies that saw either huge gains or massive losses. 24/7 Wall St. has picked a few of those standouts to highlight.
9:10am ET
Investing
Top Analyst Upgrades and Downgrades: AbbVie, Beyond Meat, Bio-Rad, Dell, HP, Jumia, Nabriva, PG&E, Salesforce, Sarepta and More
The included AbbVie, Beyond Meat, Bio-Rad Laboratories, Dell Technologies, HP, Jumia Technologies, Nabriva Therapeutics, PG&E, Salesforce.com and Sarepta Therapeutics.
6:55am ET
Investing
Merrill Lynch’s Top Second-Half 2019 Small and Midcap Stock Picks
With the market clearly close to, or at full value, it makes sense to look to areas where alpha can be generated for the rest of 2019. These five top stocks are…
12:10pm ET
Investing
Credit Suisse Best Ideas List Still Has 50% Implied Upside for 8 Stocks
With the three major stock indexes trading at or near all-time highs, many investors are scratching their heads about where to look for new investment ideas at a time when interest rates…